Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
| Image |  |
|---|---|
| Description | scientific article published on 01 February 2020 |
| Author/s |
author: David Lau Hardev Pandha Nicola Annels |
| Publication date | February 1, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |